恩格列净的一小步，糖尿病学的一大步。
One Small Step for Empagliflozin, One Giant Leap for Diabetology.
作者信息
Kalra Sanjay
机构信息
Department of Endocrinology, Bharti Hospital, Karnal, India.
出版信息
Diabetes Ther. 2015 Dec;6(4):405-409. doi: 10.1007/s13300-015-0144-9. Epub 2015 Nov 4.
Abstract
This article discusses the recently published EMPA-REG OUTCOME trial, which assessed cardiovascular outcomes with empagliflozin therapy in persons with type 2 diabetes mellitus and coexisting cardiovascular disease. The article describes the background and challenges of modern cardiovascular outcome trials, points out the strengths of the EMPA-REG OUTCOME study, and places the results in perspective. It highlights the significant impact that these results will have on cardiovascular preventive pharmacotherapy, and on future drug development in diabetes. At the same time, it reminds readers of the limitations of the results, and lists the questions raised by, or left unanswered by, the trial.
摘要
本文讨论了最近发表的EMPA-REG OUTCOME试验，该试验评估了恩格列净治疗2型糖尿病合并心血管疾病患者的心血管结局。文章描述了现代心血管结局试验的背景和挑战，指出了EMPA-REG OUTCOME研究的优势，并对结果进行了客观分析。它强调了这些结果将对心血管预防药物治疗以及糖尿病未来药物研发产生的重大影响。同时，它提醒读者注意结果的局限性，并列出了该试验引发的或未解答的问题。
相似文献
1
One Small Step for Empagliflozin, One Giant Leap for Diabetology.恩格列净的一小步，糖尿病学的一大步。
Diabetes Ther. 2015 Dec;6(4):405-409. doi: 10.1007/s13300-015-0144-9. Epub 2015 Nov 4.
2
Following the results of the EMPA-REG OUTCOME trial with empagliflozin, is it possible to speak of a class effect?依据恩格列净的EMPA-REG OUTCOME试验结果，是否可以认为存在类效应？
Int J Gen Med. 2017 Jan 13;10:23-26. doi: 10.2147/IJGM.S115566. eCollection 2017.
3
Cardiovascular effects of sodium glucose cotransporter 2 inhibitors.钠-葡萄糖协同转运蛋白2抑制剂的心血管效应
Diabetes Metab Syndr Obes. 2018 Apr 12;11:133-148. doi: 10.2147/DMSO.S154602. eCollection 2018.
4
Pleiotropic effects of SGLT2 inhibitors beyond the effect on glycemic control.钠-葡萄糖协同转运蛋白2抑制剂除了对血糖控制有影响外的多效性作用。
Diabetol Int. 2018 Aug 14;9(4):212-214. doi: 10.1007/s13340-018-0367-x. eCollection 2018 Oct.
5
Update on SGLT2 Inhibitors-New Data Released at the American Diabetes Association.SGLT2抑制剂的最新进展——美国糖尿病协会发布的新数据
Crit Pathw Cardiol. 2017 Sep;16(3):93-95. doi: 10.1097/HPC.0000000000000125.
6
Economic modelling of costs associated with outcomes reported for type 2 diabetes mellitus (T2DM) patients in the CANVAS and EMPA-REG cardiovascular outcomes trials.CANVAS和EMPA-REG心血管结局试验中2型糖尿病（T2DM）患者报告的结局相关成本的经济模型。
J Med Econ. 2019 Mar;22(3):280-287. doi: 10.1080/13696998.2018.1562817. Epub 2019 Jan 11.
7
Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus: Cardiovascular and Kidney Effects, Potential Mechanisms, and Clinical Applications.钠-葡萄糖协同转运蛋白2抑制剂在糖尿病治疗中的应用：心血管和肾脏效应、潜在机制及临床应用
Circulation. 2016 Sep 6;134(10):752-72. doi: 10.1161/CIRCULATIONAHA.116.021887. Epub 2016 Jul 28.
8
The Cardiovascular Benefits Associated with the Use of Sodium-Glucose Cotransporter 2 Inhibitors - Real-World Data.使用钠-葡萄糖协同转运蛋白2抑制剂的心血管益处——真实世界数据
Eur Endocrinol. 2018 Apr;14(1):17-23. doi: 10.17925/EE.2018.14.1.17. Epub 2018 Apr 18.
9
Impact of EMPA-REG OUTCOME on the management of type 2 diabetes mellitus: a review for primary care physicians.恩格列净心血管结局研究（EMPA-REG OUTCOME）对2型糖尿病管理的影响：基层医疗医生综述
Postgrad Med. 2016 Nov;128(8):822-827. doi: 10.1080/00325481.2016.1245093. Epub 2016 Oct 25.
10
Sodium-Glucose Co-transporter 2 (SGLT2) Inhibitor: Comparing Trial Data and Real-World Use.钠-葡萄糖协同转运蛋白2（SGLT2）抑制剂：试验数据与实际应用对比
Diabetes Ther. 2017 Apr;8(2):365-376. doi: 10.1007/s13300-017-0254-7. Epub 2017 Mar 21.
引用本文的文献
1
Lessons From LEADER - All-round Leadership.来自LEADER的经验教训——全方位领导力。
Eur Endocrinol. 2016 Aug;12(2):76-78. doi: 10.17925/EE.2016.12.02.76. Epub 2016 Aug 28.
2
Vascular legacy: HOPE ADVANCEs to EMPA-REG and LEADER: A Surprising similarity.血管遗留问题：从HOPE研究到EMPA-REG研究和LEADER研究的进展：一个惊人的相似之处。
Indian J Endocrinol Metab. 2017 Jan-Feb;21(1):245-248. doi: 10.4103/2230-8210.194341.
3
Glycemic equipoise.血糖平衡
Indian J Endocrinol Metab. 2017 Jan-Feb;21(1):18-20. doi: 10.4103/2230-8210.194361.
4
Sodium-glucose cotransporter 2 inhibition and health benefits: The Robin Hood effect.钠-葡萄糖协同转运蛋白2抑制作用与健康益处：罗宾汉效应。
Indian J Endocrinol Metab. 2016 Sep-Oct;20(5):725-729. doi: 10.4103/2230-8210.183826.
5
Follow the LEADER-Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results Trial.跟随领导者——利拉鲁肽在糖尿病中的疗效与作用：心血管结局结果试验评估
Diabetes Ther. 2016 Dec;7(4):601-609. doi: 10.1007/s13300-016-0197-4. Epub 2016 Sep 9.
本文引用的文献
1
Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes.西格列汀对 2 型糖尿病患者心血管结局的影响。
N Engl J Med. 2015 Jul 16;373(3):232-42. doi: 10.1056/NEJMoa1501352. Epub 2015 Jun 8.
2
Can cardiac autonomic neuropathy be a predictor of cardiovascular outcomes in diabetes?心脏自主神经病变能否作为糖尿病患者心血管结局的预测指标？
Indian J Endocrinol Metab. 2015 Mar-Apr;19(2):196-7. doi: 10.4103/2230-8210.145795.
3
SGLT-2 inhibitors and cardiovascular risk: proposed pathways and review of ongoing outcome trials.钠-葡萄糖协同转运蛋白2抑制剂与心血管风险：提出的作用途径及正在进行的结局试验综述
Diab Vasc Dis Res. 2015 Mar;12(2):90-100. doi: 10.1177/1479164114559852. Epub 2015 Jan 14.
4
Sodium Glucose Co-Transporter-2 (SGLT2) Inhibitors: A Review of Their Basic and Clinical Pharmacology.钠-葡萄糖协同转运蛋白2（SGLT2）抑制剂：基础与临床药理学综述
Diabetes Ther. 2014 Dec;5(2):355-66. doi: 10.1007/s13300-014-0089-4. Epub 2014 Nov 26.
5
Medication counselling with sodium glucose transporter 2 inhibitor therapy.钠葡萄糖协同转运蛋白2抑制剂治疗的用药咨询
Indian J Endocrinol Metab. 2014 Sep;18(5):597-9. doi: 10.4103/2230-8210.139206.
6
Basal insulin glargine and microvascular outcomes in dysglycaemic individuals: results of the Outcome Reduction with an Initial Glargine Intervention (ORIGIN) trial.基础胰岛素甘精胰岛素与血糖异常个体的微血管结局：初始甘精胰岛素干预降低结局（ORIGIN）试验结果
Diabetologia. 2014 Jul;57(7):1325-31. doi: 10.1007/s00125-014-3238-4. Epub 2014 Apr 26.
7
Alogliptin after acute coronary syndrome in patients with type 2 diabetes.阿格列汀治疗 2 型糖尿病合并急性冠脉综合征患者。
N Engl J Med. 2013 Oct 3;369(14):1327-35. doi: 10.1056/NEJMoa1305889. Epub 2013 Sep 2.
8
Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus.沙格列汀与 2 型糖尿病患者的心血管结局。
N Engl J Med. 2013 Oct 3;369(14):1317-26. doi: 10.1056/NEJMoa1307684. Epub 2013 Sep 2.
9
Randomized clinical trial of quick-release bromocriptine among patients with type 2 diabetes on overall safety and cardiovascular outcomes.随机临床试验快速释放溴隐亭 2 型糖尿病患者的整体安全性和心血管结局。
Diabetes Care. 2010 Jul;33(7):1503-8. doi: 10.2337/dc09-2009. Epub 2010 Mar 23.
10
Effect of muraglitazar on death and major adverse cardiovascular events in patients with type 2 diabetes mellitus.muraglitazar对2型糖尿病患者死亡及主要不良心血管事件的影响。
JAMA. 2005 Nov 23;294(20):2581-6. doi: 10.1001/jama.294.20.joc50147. Epub 2005 Oct 20.
Zotero 插件